Roth MKM notes that TriSalus Life Sciences (TLSI) has appointed a new Chief Financial Officer, James Young, to replace Sean Murphy, who will continue to serve the company as Chief Manufacturing, Strategy, and Business Development Officer. Young was already closely involved in the business and the firm expects “continued strong execution,” says the analyst, who reiterates a Buy rating and $11 price target on TriSalus shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences appoints James Young CFO, Richard Marshak CCO
- TriSalus Life Sciences initiated with an Overweight at Cantor Fitzgerald
- TriSalus Life Sciences management to meet with Maxim
- TriSalus Life Sciences price target lowered to $11 from $12 at Canaccord
- TriSalus Life Sciences Reports Strong Q3 Growth
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue